LAW – Talk Bio

New NIH grant rules override the Civil Rights Act of 1964, barring recipients from DEI activities

2 days ago talkbio0Tagged 1964, Changing, civil, Civil Rights Act, Condition, Diversity, federal, Israeli (population group), NIH, Policy, Protections, recipients, United States National Institutes of Health

United States National Institutes of Health, recipients, NIH, Policy, Diversity, Changing, Condition, civil, federal, civil, protections, recipients, Israeli (population group), Civil Rights Act, 1964

Amgen Secures Phase 3 Survival Data for Imdelltra in Small-Cell Lung Cancer, Strengthening Its Case for Full FDA Approval

1 week ago talkbio0Tagged amgen, Biological Factors, DLL3-targeting therapy, Imdelltra, Immunotherapy, Overall Survival, Phase 3 trial, SCLC, small-cell lung cancer

Imdelltra, Amgen, Small-cell lung cancer (SCLC), Phase 3 trial, Overall survival, DLL3-targeting therapy, Immunotherapy, Biopharmaceuticals

Alzheon Investigates Subgroup Data Following Phase 3 Trial of ALZ-801 in Alzheimer’s Disease

2 weeks ago talkbio0Tagged ALZ-801, Alzheimer 's disease, Amyloid-targeting therapy, Apolipoprotein E4, Genotype, Mental deterioration, Mild cognitive disorder, Phase 3 trial, Precision Medicine, Subgroup A Nepoviruses, Valiltramiprosate

Alzheimer’s disease , ALZ-801 , Valiltramiprosate , APOE4 genotype , Mild cognitive impairment (MCI) , Amyloid-targeting therapy , Phase 3 trial results , Cognitive decline , Subgroup analysis , Precision medicine

Tempest Seeks Strategic Partners to Launch Phase 3 Liver Cancer Trial Amid Funding Challenges

2 weeks ago talkbio0Tagged altretamine/cisplatin/cyclophosphamide protocol, amezalpat, Avastin, biotech, Clearance, Clinical Oncology, Liver and Intrahepatic Biliary Tract Carcinoma, partnerships, Peroxisome Proliferator-Activated Receptors, Phase 3 trial, strategic, Tecentriq, United States Food and Drug Administration

Tempest Therapeutics , Amezalpat , Phase 3 Trial , Liver Cancer (HCC) , Strategic Partnerships , Biotech Funding , PPAR⍺ Antagonist , Clinical Oncology , FDA Clearance , Tecentriq and Avastin Combination Therapy

Annexon Advances Guillain-Barré Syndrome Awareness and Introduces Groundbreaking Targeted Therapy

2 weeks ago talkbio0Tagged Annexon, ANX005, Approved, GBS, Guillain-Barré syndrome, Move GBS Forward™, Phase 3, Phase 3 trial, Tanruprubart, Targeted Therapy, United States Food and Drug Administration

Guillain-Barré Syndrome (GBS) , Annexon , Tanruprubart (ANX005) , Targeted therapy , GBS education campaign , Move GBS Forward™ , Phase 3 trial results , FDA approval

Rallybio Halts Development of Lead FNAIT Program Following Phase 2 Failure

2 weeks ago talkbio0Tagged Alloimmune thrombocytopenia, Biotech pipeline shift, Fetal and neonatal alloimmune thrombocytopenia, Fetus, immune disorder therapy, Infant, Newborn, Mother (person), Phase 2 clinical trial, Rallybio RLYB212

Rallybio RLYB212, Fetal and neonatal alloimmune thrombocytopenia (FNAIT), Phase 2 clinical trial, Maternal immune disorder therapy, Biotech pipeline shift